News

December 11, 2018
Asahi Kasei Pharma launches Kevzara® autoinjector for treatment of rheumatoid arthritis
December 3, 2018
Addition of Kevzara® to category of drugs subject to guidance and management fee for self-injection at home and lift of ban on long-term prescription
October 30, 2018
Application for approval to manufacture and sell Teribone™ autoinjector
August 2, 2018
Preliminary results of overseas Phase III clinical study for ART-123
July 24, 2018
Asahi Kasei Pharma signs distribution agreement with Stanbio Laboratory for the marketing of Lucica® Glycated Albumin-L in the US
March 26, 2018
License agreement for novel P2X7 receptor antagonist
February 5, 2018
Asahi Kasei Pharma launched Kevzara® Subcutaneous Injection, a treatment for rheumatoid arthritis, in Japan
December 8, 2017
Sanofi and Asahi Kasei Pharma enter license agreement for marketing of Kevzara® Subcutaneous Injection, a treatment for rheumatoid arthritis, in Japan
November 30, 2017
Maruho and Asahi Kasei Pharma Announce Phase 3 Clinical Study Results of Famciclovir for the Treatment of Recurrent Herpes Simplex
October 20, 2017
Asahi Kasei Pharma received 510(k) clearance from the FDA for Lucica® Glycated Albumin-L
June 5, 2017
Application for import drug registration for Flivas™ (naftopidil) in China
May 18, 2017
Asahi Kasei Pharma receives approval to extend treatment duration for Teribone™ osteoporosis drug
January 12, 2017
Announcement of marketing of Bredinin™ OD25 and Bredinin™ OD50
November 18, 2016
Announcement of listing on the NHI drug price standard and marketing of Reclast®
September 28, 2016
Approval for manufacture and sale of Reclast® in Japan
September 15, 2016
License agreement for new antifungal agent
August 5, 2016
Completion of a new pharmaceutical manufacturing facility in Fuji
July 22, 2016
Application to extend duration of treatment for Teribone™ osteoporosis drug
June 22, 2016
Global strategic collaboration with Orion Corporation
April 1, 2016
License agreement for chronic pain drug
Page Top